Advertisement

Pharmaceutical Chemistry Journal

, Volume 45, Issue 7, pp 415–418 | Cite as

Essential biopharmaceutical properties of drugs at the gastrointestinal absorption stage (Review)

  • I. E. Shokhin
  • Yu. I. Kulinich
  • G. V. Ramenskaya
  • V. G. Kukes
Drug Synthesis Methods and Production Techniques

The essential biopharmaceutical properties affecting the ability of drugs to reach the systemic circulation are discussed. Properties such as biopharmaceutical solubility and intestinal permeability are described, along with methods of assessing them and interactions between drug transport and absorption across GIT membranes and levels of metabolism. The main biopharmaceutical classification systems for drugs are presented and their use in regulatory practice is discussed.

Key words

Solubility absorption permeability metabolism biopharmarceutical classification system (BCS) biopharmaceutical drug disposition classification system (BDDCS) based on solubility and metabolism biowaiver 

References

  1. 1.
    G. L. Amidon and H. Lennerlas, V. P. Shah, and J. R. Crimson, Pharm. Res., No. 12, 413 – 420 (1995).Google Scholar
  2. 2.
    United States Pharmacopeia and National Formulary, USP 31-NF, 26 (2008), Rockville, MD, USA: The United Pharmacopeial Convention (2008).Google Scholar
  3. 3.
    Guidance for Industry: Waiver of in vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, US Department of Health and Human Services, Food and Drug Administration (HHS-FDA), Center for Drug Evaluation and Research (CDER) (2000).Google Scholar
  4. 4.
    Proposal to Waive in vivo Bioequivalence Requirements for WHO Model List of Essential Medicines Immediate-Release, Solid Oral Dosage Forms, Technical Report Series, No. 937, 40th Report, Annex 8 of WHO Expert Committee on Specifications for Pharmaceutical Preparations, World Health Organization (WHO) (2008).Google Scholar
  5. 5.
    Guidance the Investigation of Bioequivalence, European Medicines Agency (EMA), Committee for Medicine Products of Human Use (CHMP) (2010).Google Scholar
  6. 6.
    M. Tubic-Grozdanis, M. B. Bolger, and P. Langguth, AAPS J., 10(1), 213 – 226 (2008).PubMedCrossRefGoogle Scholar
  7. 7.
    M. Yasir, M. Asif, A. Kumar, and A. Aggarval, Int. J. Pharm. Tech. Res., 2(3), 1681 – 1690 (2010).Google Scholar
  8. 8.
    L. Thorsteinn and H. Daghy, AAPS Pharm. Sci. Tech., 7(1), (2006). Article 4. URL: http://wwww.aapspharmscitech.org/articles/pt0701/pt070104.pdf (checked on 20 September 2010).
  9. 9.
    M. Yazdanian, K. Briggs, C. Jankovsky, and A. Hawi, Pharm. Res., 21, 293 – 299 (2004).PubMedCrossRefGoogle Scholar
  10. 10.
    Database of the Federal State Agency “Therapeutic Products Regulatory Research Centre,” Russian Ministry of Health and Social Development. URL: http://www.regmed.ru (checked on 20 September 2010).
  11. 11.
    International Pharmaceutical Federation (FIP). Biopharmaceutics Classification System (BCS). URL: http://www.fip.org/bcs (checked on 20 September 2010).
  12. 12.
    Methodological Guidelines for Drug Developers and Manufacturers in Relation to the in vitro Evaluation of the Equivalence of Generic Drugs by the ‘Biowaiver’ Procedure [in Russian], Ratified by Roszadravnadzor, 2010, Remedium Press, Moscow (2010).Google Scholar
  13. 13.
    N. A. Kasim, M. Whitehouse, C. Ramachandran, et al., Mol. Pharm., 1(1), 85 – 96 (2004).PubMedCrossRefGoogle Scholar
  14. 14.
    E. Rinaki, P. Valsami, and P. Macheras, Pharm. Res., 20, 1917 – 1925 (2003).PubMedCrossRefGoogle Scholar
  15. 15.
    J.-S. Kim, S. Mitchell, P. Kijek, et al., Mol. Pharm., 3(6), 686 – 694 (2006).PubMedCrossRefGoogle Scholar
  16. 16.
    H. Vogelpoel, J. Welink, and G. L. Amidon, et al., J. Pharm. Sci., 93, 1945 – 1956 (2004).PubMedCrossRefGoogle Scholar
  17. 17.
    S. Yee, Pharm. Res., 14(6), 763 – 766 (1997).PubMedCrossRefGoogle Scholar
  18. 18.
    A. Dahan, J. M. Miller, and G. L. Amidon, AAPS J., 11(6), 740 – 746 (2009).PubMedCrossRefGoogle Scholar
  19. 19.
    C.-Y.Wu and L. Benet, Pharm. Res., 22, No. 1, 11 – 23 (2005).PubMedCrossRefGoogle Scholar
  20. 20.
    S. V. Grachev, V. G. Kukes, D. A. Sychev, and G. V. Ramenskaya, Drug Metabolism. The Scientific Basis of Personalized Medicine [in Russian], GÉOTAR-Media, Moscow (2008).Google Scholar
  21. 21.
    I. E. Shokhin, G. V. Ramenskaya, G. F. Vasilenko, and E. A. Malashenko, Farmatsiya, 5, 13 – 15 (2010).Google Scholar
  22. 22.
    L. Benet, G. L. Amidon, D. Barends, et al., Pharm. Res., 52(3), 483 – 488 (2008).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2011

Authors and Affiliations

  • I. E. Shokhin
    • 1
    • 2
  • Yu. I. Kulinich
    • 1
    • 2
  • G. V. Ramenskaya
    • 1
    • 2
    • 3
  • V. G. Kukes
    • 1
    • 2
    • 3
  1. 1.MoscowRussia
  2. 2.MoscowRussia
  3. 3.MoscowRussia

Personalised recommendations